AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kamada will announce Q3 and nine months financial results for September 30, 2025, on November 10, 2025. Management will host an investor call to discuss the results. The company's portfolio includes six FDA-approved specialty plasma-derived products and three plasma collection centers in the US. The company is also developing Inhaled AAT for areas of unmet medical need.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet